Akero Therapeutics Inc
NASDAQ:AKRO
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
25.02
57.56
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Operating Margin
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
Peer Comparison
| Country | Company | Market Cap |
Operating Margin |
||
|---|---|---|---|---|---|
| US |
|
Akero Therapeutics Inc
NASDAQ:AKRO
|
4.4B USD |
Loading...
|
|
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD |
Loading...
|
|
| US |
|
Abbvie Inc
NYSE:ABBV
|
378.3B USD |
Loading...
|
|
| US |
|
Amgen Inc
NASDAQ:AMGN
|
178.1B USD |
Loading...
|
|
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
154.2B USD |
Loading...
|
|
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
112.3B USD |
Loading...
|
|
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR |
Loading...
|
|
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
77.3B USD |
Loading...
|
|
| AU |
|
CSL Ltd
ASX:CSL
|
85.3B AUD |
Loading...
|
|
| NL |
|
argenx SE
XBRU:ARGX
|
41.7B EUR |
Loading...
|
|
| US |
|
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
|
46.9B USD |
Loading...
|
Market Distribution
Other Profitability Ratios
Akero Therapeutics Inc
Glance View
Akero Therapeutics Inc. is a biopharmaceutical company deeply anchored in the quest to tackle some of the most pressing challenges in healthcare through its innovative approach to chronic liver diseases. Founded with the vision of transforming treatment paradigms, Akero is primarily focused on developing therapies for non-alcoholic steatohepatitis (NASH), a serious liver condition that currently lacks FDA-approved treatments. The company’s lead asset, EFX, is a precision-engineered FGF21 analog that targets the underlying causes of NASH by improving lipid and glucose metabolism, reducing inflammation, and reversing fibrosis. This drug candidate encapsulates the company’s mission of leveraging scientific innovation to address significant unmet medical needs. Akero’s business model is built on pioneering research, which it hopes will translate into lucrative commercial opportunities. The company invests heavily in clinical trials to demonstrate the efficacy of its therapies, aiming to secure regulatory approvals that pave the path for market entry. By advancing EFX through various phases of clinical studies, Akero strives to establish a foothold in the burgeoning NASH market, projected to become a multi-billion dollar industry. Revenues are anticipated from eventual drug sales, partnered collaborations, and potentially out-licensing deals. In essence, Akero’s approach is a calculated blend of scientific exploration and strategic market navigation, where success hinges on both innovative drug development and adept management of regulatory and commercial pathways.